Nuclease Probe Technologies
Nuclease Probe Technologies: Rapid infection testing and antibiotic guidance for improved patient care.
Founded
2014Nuclease Probe Technologies: Rapid infection testing and antibiotic guidance for improved patient care.
Nuclease Probe Technologies was founded with the mission to revolutionize infection testing and antibiotic guidance through rapid, phenotypic antibiotic susceptibility tests. Their core vision is to enable faster, more informed treatment decisions for both veterinarians and physicians, ultimately improving patient outcomes. The company offers products such as the NucAP™ Pyoderma Tri-plates, which provide rapid diagnostics for veterinary medicine, specifically targeting antibiotic susceptibilities of canine skin pathogens with an 8-hour turnaround time.
Notable figures affiliated with Nuclease Probe Technologies include key researchers and industry experts in microbiology and veterinary medicine. The company has attracted significant interest from investors focused on healthcare innovation. Among its key achievements is the development of a novel diagnostic platform that significantly reduces the time required for antibiotic susceptibility testing. This advancement has had a substantial impact on veterinary practices, enabling quicker and more accurate treatment decisions, thereby improving the health and recovery rates of animal patients.
Companies similar to Nuclease Probe Technologies include Specific Diagnostics, NuProbe, Nuclein and NAT Diagnostics.
Nuclease Probe Technologies was founded in 2014.
Nuclease Probe Technologies' headquarters is located in Boston, MA, US.
Nuclease Probe Technologies' most recent funding round was for $500k (USD) in March 2019.
As of Mar 7, 2019, Nuclease Probe Technologies has raised a total of $500k (USD).
Nuclease Probe Technologies has 5 employees as of Feb 4, 2024.
Nuclein
nuclein.com
